You are here: Industry Insights > Novartis

News List

Novartis next generation eye drug outperforms Eylea pharmaphorum
June 22, 2017
Novartis is to file its next-generation eye drug in 2018 after it won out in a head-to-head trial with Bayer/Regeneron’s rival, Eylea.
Novartis files migraine drug with EMA pharmaphorum
June 22, 2017
Novartis has filed its migraine drug erenumab with the EMA, putting it in pole position among a group of pharma companies racing to develop a new class of drugs to treat the debilitating condition.
Novartis Gets Creative in Pricing Next-Generation Cancer Therapy bloomberg
June 08, 2017
Novartis AG, set to beatKite Pharma Inc. to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.
BMS, Novartis to test Mekinist/Opdivo combo pharmatimes
June 07, 2017
Novartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo.
Novartis, Bristol-Myers Squibb to Evaluate Potential Metastatic Colorectal Cancer Treatments americanpharmaceuticalreview
June 07, 2017
Novartis announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability...
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in ad cphi-online
June 06, 2017
Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer.
FDA approves expanded use of Novartis’ lung cancer drug Zykadia europeanpharmaceuticalreview
May 31, 2017
The US Food and Drug Administration (FDA) approved the expanded use of Novartis’ Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC)...
Novartis and Pakistan sign deal to provide free medicine for chronic diseases pharmaceutical-technology
May 16, 2017
Ministry of National Health Services, Regulations and Coordination of Pakistan and Novartis have signed a memorandum of understanding (MoU) to increase access to treatment for poor people affected with chronic diseases.
Novartis signs drug access deal with Pakistan government pharmafile
May 15, 2017
Pakistan’s Ministry of National Health Services, Regulations and Coordination has signed an agreement with Novartis to improve access to medicines for chronic disease.
Novartis receives FDA approval for Kisqali Femara Co-Pack to treat metastatic breast cancer pharmaceutical-technology
May 11, 2017
Novartis has received the US Food and Drug Administration (FDA) approval for the Kisqali Femara Co-Pack to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+ / HER2-) advanced or metastatic breast cancer in postmenopau

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page